After Seelos Therapeutics’ amyotrophic lateral sclerosis (ALS) candidate failed a phase 2/3 study, the biotech has filed for ...
Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback